Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Teprasiran (Primary)
- Indications Delayed graft function
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Quark Pharmaceuticals
- 06 Jun 2018 Results of negative binomial model determining DGF severity difference between groups from subset of donors of QRK006B study presented at the 2018 American Transplant Congress
- 31 Jul 2014 Results presented at the World Transplant Congress 2014.
- 01 Jul 2014 According to the Quark Pharmaceuticals media release, results from this trial will be presented at the World Transplant Congress 2014 on 26 - 31 Jul 2014.